Identification | Back Directory | [Name]
1-(7-Methoxyquinolin-4-yl)-3-[6-(trifluoromethyl)pyridin-2-yl]urea | [CAS]
1384424-80-9 | [Synonyms]
A-1070722 N-(7-Methoxy-4-quinolinyl)-N&rsquo -[6-(trifluoromethyl)-2-pyridinyl]urea 1-(7-Methoxyquinolin-4-yl)-3-[6-(trifluoromethyl)pyridin-2-yl]urea N-(7-Methoxy-4-quinolinyl)-N'-[6-(trifluoromethyl)-2-pyridinyl]urea Urea, N-(7-methoxy-4-quinolinyl)-N'-[6-(trifluoromethyl)-2-pyridinyl]- | [Molecular Formula]
C17H13F3N4O2 | [MDL Number]
MFCD22580422 | [MOL File]
1384424-80-9.mol | [Molecular Weight]
362.31 |
Chemical Properties | Back Directory | [Boiling point ]
412.5±45.0 °C(Predicted) | [density ]
1.461±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: soluble15mg/mL, clear | [form ]
powder | [pka]
11.57±0.43(Predicted) | [color ]
white to beige |
Hazard Information | Back Directory | [Description]
A-1070722 is an inhibitor of glycogen synthase kinase 3β (GSK3β; IC50 = <100 nM). | [Uses]
N-(7-Methoxy-4-quinolinyl)-N''-[6-(trifluoromethyl)-2-pyridinyl]urea is a neuroprotective agent and a glycogen synthase kinase-3 (GSK-3) inhibitor. GSK-3 is a conserved signaling enzyme that regulates a wide range of biological events (apoptosis, synaptic plasticity, axon formation, and neurogenesis). The enzyme has a conserved catalytic domain for binding ATP and a C-terminal domain with a conserved activation loop for the kinase activity. GSK-3 is a therapeutic target for treating neurodegenerative and psychiatric disorders. | [in vivo]
A 1070722 (10-20 mg/kg, 30 min before cocaine injection or 30 min prior to injection with saline (test day)) decreases spontaneous locomotion, inhibits the expression of conditioned activities but not the acquisition of conditioned activities in Cocaine-paired rats[2].
| [IC 50]
GSK-3α: 0.6 nM (Ki); GSK-3β: 0.6 nM (Ki) | [storage]
Store at RT |
|
Company Name: |
BOC Sciences
|
Tel: |
|
Website: |
https://www.bocsci.com |
Company Name: |
Energy Chemical
|
Tel: |
021-58432009 400-005-6266 |
Website: |
http://www.energy-chemical.com |
|